webleads-tracker

US Sunshine Act

AVMA Board of Directors calls for more discussion on the Veterinarian Payments Sunshine Act

After careful review and examination by several volunteer committees, the American Veterinary Medical Association (AVMA) Board of Directors at its Jan. 8 meeting decided to take a position of “no action” on the Veterinarian Payments Sunshine Act, which has not yet been introduced in Congress. The Board believes that any new regulations imposed on the veterinary profession to disclose conflicts of interest should be rooted in a better understanding of if and where there are issues and has called for further examination of this topic by its expert leaders. For those unfamiliar with the the act, it mimics the Physician …

Read More »

Physician Payments Sunshine Act database: Which specialties receive the highest payments?

The Centers for Medicare and Medicaid Services‘ Open Payments program implements Section 6002 of the Affordable Care Act requiring medical product manufacturers to report payments made to physicians or teaching hospitals as well as ownership or investment interests held by physicians in the manufacturer. To determine the characteristics and distribution of these industry payments by specialty, we analyzed physician payments made between August 1, 2013, and December 31, 2013, that were publicly disclosed by Open Payments. We compared payments between specialty types (medical, surgical, and other) and across specialties within each type using the Pearson χ2 test and the Kruskal-Wallis …

Read More »

Banning TV Drug Ads: Could the Cure Cause More Harm Than Good?

Direct-to-consumer (DTC) advertising in the U.S. of prescription drugs and medical devices is in the spotlight, with the American Medical Association (AMA) calling for a ban on it. The Chicago-based physicians group issued a statement last month that it has adopted a policy to block such advertising. The AMA’s chief argument is that the “growing proliferation of ads is driving demand for expensive treatments despite the clinical effectiveness of less costly alternatives.” Patrice A. Harris, chair-elect of the AMA, added: “Direct-to-consumer advertising also inflates demand for new and more expensive drugs, even when these drugs may not be appropriate.” The …

Read More »

Senate Finance Committee Hearing on Physician Owned Distributorships (PODs) Highlights the Complexity of the Issue

Transparence santé, Sunshine Act

November 20, 2015 by Thomas Sullivan The Senate Finance Committee has been conducting an investigation into Physician Owned Distributorships (PODs), leading to at least one referral to the Health and Human Services Office of Inspector General for potential action, the case of a device manufacturer who offered to make payments to doctors through a third party to avoid disclosure. To read the article by Policy & Medicine

Read More »

Open Payments: Research Payments Distorted by Including Value of the Medicines and Devices

Transparence santé, Sunshine Act

October 20, 2015. By Thomas Sullivan. The Open Payments program, an element of the Affordable Care Act (the « Sunshine Act »), has required the healthcare industry to adhere to a complex transparency program since its implementation in 2014. The Act is an attempt to track payments and transfers of value between life sciences manufacturers and healthcare professionals, and requires any payments and transfers of value to be reported publicly on the Open Payments website. Many have been concerned that such a requirement has the potential to do more harm than good, especially since the reliability of the data has been called …

Read More »